Skip to content
HowShorted

Tarsus Pharmaceuticals, Inc. short interest in 2023

In 2023, Tarsus Pharmaceuticals, Inc.'s disclosed short interest ran from 3.89% of shares outstanding on 13 Jan 2023 to 15.11% on 29 Dec 2023, a change of +11.22 percentage points. The year's high was 15.22% on 29 Sep 2023 and its low 3.19% on 15 May 2023, averaging 8.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.35 days on 14 Jul 2023. Full history: Tarsus Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tarsus Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
3.89% (13 Jan 2023)
End of year
15.11% (29 Dec 2023)
Change
+11.22 pp
High
15.22% (29 Sep 2023)
Low
3.19% (15 May 2023)
Average
8.82%
Highest days to cover
27.35 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Tarsus Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20233.89%13.85
31 Jan 20233.63%8.18
15 Feb 20233.70%24.74
28 Feb 20233.74%17.16
15 Mar 20233.90%17.28results (8-K)
31 Mar 20233.71%11.3510-K filed
14 Apr 20233.59%6.81
28 Apr 20233.59%3.55
15 May 20233.19%6.9210-Q filed, results (8-K)
31 May 20233.40%4.84
15 Jun 20235.89%6.44
30 Jun 20238.37%7.61
14 Jul 20238.56%27.35
31 Jul 202314.20%4.67
15 Aug 202313.73%6.3610-Q filed, results (8-K)
31 Aug 202313.82%18.48
15 Sep 202313.47%9.61
29 Sep 202315.22%13.89
13 Oct 202312.26%7.14
31 Oct 202312.87%9.99
15 Nov 202313.47%6.1410-Q filed, results (8-K)
30 Nov 202313.45%7.14
15 Dec 202314.83%7.64
29 Dec 202315.11%6.85

See also: Tarsus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.